The short answer
Thymosin beta-4 is the principal G-actin sequestering protein in many cell types: it binds actin monomers and holds them unpolymerised, maintaining a reservoir that can be released for rapid filament assembly. TB-500 carries the motif associated with that binding.
Key facts
- Target
- G-actin (monomeric actin)
- Effect
- Prevents incorporation into filaments
- Purpose
- Maintains a monomer reservoir
- Tβ4 role
- Principal sequestering protein in many cells
- F-actin
- Filamentous form (not the target)
- Evidence
- Well established for the protein
Two forms of actin
Actin exists as free monomers, G-actin, and as polymerised filaments, F-actin. The cytoskeleton is built from filaments, and cells constantly build and dismantle them, for movement, division, and changing shape. The rate at which a cell can do this depends on how much monomer is available to polymerise.
Why a cell would hold monomers back
This is the counterintuitive part. Sequestering actin sounds like suppressing the cytoskeleton, and it is closer to the opposite. Free G-actin above a critical concentration polymerises spontaneously and uncontrollably. Holding a large monomer pool bound keeps it out of filaments while keeping it immediately available, so the cell can assemble filaments quickly, where it chooses, rather than having actin polymerise everywhere at once.
Research material referenced
TB-500 5mg, third-party HPLC tested
The reservoir analogy
A sequestering protein functions like a dam rather than a drain. The stored monomer is not discarded; it is held under control and released on demand. This is why thymosin beta-4 is described as enabling rapid cytoskeletal remodelling despite its immediate action being inhibitory.
How this connects to the reported effects
Cell migration requires continual cytoskeletal reorganisation, filaments assembling at the leading edge and disassembling behind. Anything altering monomer availability plausibly affects that process, which is the mechanistic bridge between actin sequestration and the migration and repair literature. The bridge is coherent; it is not the same as demonstrated in the systems where repair was observed.
What applies to the fragment
Actin sequestration is well established for full-length thymosin beta-4. TB-500 carries the motif associated with it, and this is the activity that transfers to the fragment most defensibly. Effects further downstream, migration, angiogenesis, repair,were largely characterised with the protein.
Frequently asked questions
Does sequestering actin suppress the cytoskeleton?
No. It maintains a controlled reservoir. Unbound monomer above a critical concentration polymerises spontaneously; holding it bound keeps it available for assembly where the cell chooses.
Does TB-500 bind filaments?
The target is monomeric G-actin, not filamentous F-actin.
Is this established for the fragment or the protein?
Well established for the protein. The fragment carries the associated motif, which is why this activity transfers most defensibly.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedHannappel E, beta-Thymosins: Ann N Y Acad Sci 2007 (PMID 17468232)pubmed.ncbi.nlm.nih.gov
- PubMedMorita T et al., G-actin sequestering protein thymosin-β4. Biochem Biophys Res Commun 2013 (PMID 23811404)pubmed.ncbi.nlm.nih.gov
- PubMedGoldstein AL et al. Expert Opin Biol Ther 2012 (PMID 22074294)pubmed.ncbi.nlm.nih.gov
- PubMedShrivastava S et al., Thymosin beta4 and cardiac repair. Ann N Y Acad Sci 2010 (PMID 20536454)pubmed.ncbi.nlm.nih.gov
- PubMedSosne G et al., Thymosin beta 4 promotes corneal wound healing. Exp Eye Res 2002 (PMID 11950239)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · Thymosin β4 (RGN-259) dry eye Phase 3 (NCT03925727)clinicaltrials.gov
- PubChemPubChem · Thymosin β4 (CID 16132341)pubchem.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More TB-500 (Thymosin β4 fragment) articles
- How Thymosin Beta-4 Was DiscoveredLow and colleagues published the complete sequence of bovine thymosin beta-4 in PNAS in February 1981, describing it as a thymic hormone. That framing changed.
- TB-500: Structure and Where It Comes FromSeven residues taken from the middle of a 43-residue protein, with an acetylated N-terminus. What that construction implies about its properties.
- TB-500 Molecular Structure and Physical Properties889.0 Da, C38H68N10O14, no cysteine or methionine, no aromatic residue. The physical consequences of a short, highly charged, flexible peptide.
- TB-500 Storage, Stability and ReconstitutionNo cysteine, methionine or asparagine, so the usual degradation routes do not apply. Adsorption to surfaces is the loss mechanism that actually matters.
- TB-500 Half-Life and ClearanceA seven-residue peptide with no half-life extension carries no protection against renal filtration or peptidases. Why acetylation helps only at one end.